Moderna, Inc.
(NASDAQ : MRNA)

( )
MRNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.16%151.450.0%$1218.54m
AMGNAmgen, Inc. 0.00%249.951.3%$706.86m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.000.7%$559.23m
NVAXNovavax, Inc. -0.67%193.3580.0%$536.05m
ILMNIllumina, Inc. 0.00%403.153.5%$527.32m
GILDGilead Sciences, Inc. 0.00%64.891.0%$472.42m
REGNRegeneron Pharmaceuticals, Inc. 0.62%480.002.7%$433.79m
VRTXVertex Pharmaceuticals, Inc. 0.00%215.941.9%$372.06m
ALXNAlexion Pharmaceuticals, Inc. 0.00%153.732.0%$315.33m
BIIBBiogen, Inc. 0.00%266.191.7%$292.97m
BNTXBioNTech SE -0.19%129.400.0%$218.39m
EXASEXACT Sciences Corp. 0.00%128.0018.4%$194.86m
NBIXNeurocrine Biosciences, Inc. 0.00%92.974.9%$172.50m
CRSPCRISPR Therapeutics AG 0.91%121.980.6%$170.89m
OCGNOcugen, Inc. 2.68%6.890.0%$150.48m

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.